4.1 The committee noted that the clinical evidence showed Optilume to be effective in improving clinically relevant outcomes including anatomical success, peak flow rate and international prostate ...
PORTSMOUTH, N.H., Jan. 17, 2025 /PRNewswire/ -- Laborie Medical Technologies Corp. (Laborie), a leader in diagnostic and therapeutic medical technologies, has reached a significant milestone with its ...
The Optilume device includes a balloon coated with paclitaxel. The Food and Drug Administration (FDA) has approved the Optilume ® Urethral Drug Coated Balloon (DCB) to treat patients with obstructive ...
Laborie Announces First Procedures in ENDURE 1 Study with the Optilume® Ureteric Drug-Coated Balloon
Landmark procedures launch the ENDURE 1 clinical study evaluating Optilume's safety and feasibility as a new minimally invasive option for patients with benign ureteric strictures. PORTSMOUTH, N.H., ...
Plymouth-based medical device maker Urotronic is ramping up clinical research on its Optilume drug-coated balloon to treat men with narrowed urethras, accelerating the data-gathering process for its ...
The approval represents an important milestone in establishing the reimbursement pathway for this novel technology in the U.S. PORTSMOUTH, N.H., Nov. 7, 2022 /PRNewswire/ -- Laborie Medical ...
PORTSMOUTH, N.H., Oct. 28, 2024 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company, Laborie Medical Technologies Corp (Laborie), announced today that the American Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results